Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P51178

UPID:
PLCD1_HUMAN

ALTERNATIVE NAMES:
Phosphoinositide phospholipase C-delta-1; Phospholipase C-III; Phospholipase C-delta-1

ALTERNATIVE UPACC:
P51178; B3KR14; Q86VN8

BACKGROUND:
Phospholipase C-delta-1, with alternative names Phospholipase C-III and Phosphoinositide phospholipase C-delta-1, is essential for the production of DAG and IP3, second messengers involved in cell signaling. Its binding to phosphatidylinositol 4,5-bisphosphate underscores its significance in cellular signaling pathways, particularly in trophoblast and placental development.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in a specific nail disorder, the study of Phospholipase C-delta-1's function and mechanisms offers promising avenues for the development of targeted therapies. Understanding the role of Phospholipase C-delta-1 could open doors to potential therapeutic strategies, enhancing our ability to treat and manage conditions associated with its dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.